Sun Pharmaceuticals and Philogen’s Pact to Commercialise Cancer Medicine Fibromun
Partnership Overview
Sun Pharmaceutical Industries Ltd. has entered into an agreement with Italian-Swiss firm Philogen to commercialise Fibromun—an anti-cancer immunotherapy drug. This partnership is a milestone in the quest for effective cancer medicine.
Clinical Trials and Progress
Fibromun is being investigated in registration trials by Philogen for treating soft tissue sarcoma and glioblastoma. Philogen is tasked with completing the ongoing pivotal clinical trials, pursuing marketing authorisation with regulatory authorities, and manufacturing commercial supplies.
Financial Collaboration
- The two partner companies will share post-commercialisation economics in a 45 (Philogen):55 (Sun Pharma) ratio.
Potential Impact on Cancer Treatment
Progress through development for Fibromun has shown encouraging results, making it a potential option for treating tumors with significant unmet medical needs. Dilip Shanghvi, chairman and managing director of Sun Pharma, highlighted the importance of this partnership in expanding treatment options.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.